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 22 
Abstract: 23 
Background:  Since the initial description of Middle East Respiratory Syndrome Coronavirus 24 
(MERS-CoV), we adopted a systematic process of screening admitted patients with community 25 
acquired pneumonia.  Here, we report the result of the surveillance activity in a general hospital 26 
in Saudi Arabia over a four year period.    27 
Materials and Methods:  All admitted patients with community acquired pneumonia from 2012 28 
to 2016 were tested for MERS-CoV.  In addition, testing for influenza viruses was carried out 29 
starting April 2015.   30 
Results:  During the study period, a total of 2657 patients were screened for MERS-CoV and 31 
only 20 (0.74%) tested positive.  From January 2015 to December 2016, a total of 1644 patients 32 
were tested for both MERS-CoV and influenza.  None of the patients tested positive for MERS-33 
CoV and 271 (16.4%) were positive for influenza.  The detected influenza viruses were Influenza 34 
A (107, 6.5%), pandemic 2009 H1N1 (n= 120, 7.3%), and Influenza B (n=44, 2.7%).  Pandemic 35 
H1N1 was the most common influenza in 2015 with a peak in peaked October to December and 36 
influenza A other than H1N1 was more common in 2016 with a peak in August and then October 37 
to December.   38 
Conclusions:  MERS-CoV was a rare cause of community acquired pneumonia and other viral 39 
causes including influenza were much more common.  Thus, admitted patients are potentially 40 
manageable with Oseltamivir or Zanamivir therapy.     41 
 42 
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 43 
Introduction: 44 
The emergence of the Middle East respiratory syndrome coronavirus (MERS-CoV) in September 45 
2012 had attracted international attention.  The virus was initially isolated from a patient with a 46 
fatal community acquired pneumonia (CAP) in Saudi Arabia [1].  Since then, multiple hospital 47 
outbreaks occurred within Saudi Arabia [2–7] and outside Saudi Arabia [8–11].  As of May 1st, 48 
2017, the World Health Organization reported 1952 laboratory-confirmed cases worldwide and 49 
at least 693 related deaths [12].  A wide-spectrum of MERS-CoV infection was described and 50 
ranges from mild to severe and fulminant infections leading to severe acute respiratory disease 51 
[2,13–15].  In the Kingdom of Saudi Arabia, the number of MERS-CoV cases was 1601 as of 52 
May 6th, 2017 [16].  Since most of the cases of MERS-CoV in Saudi Arabia occurred due to 53 
intra- and inter-hospital transmissions, there was an increased amplification of the transmission 54 
[2–4,9–11,17].  Early detection and isolation of patients with MERS-CoV infection remains an 55 
important factor for the control of MERS-CoV transmission [18,19].   One of the goals of the 56 
surveillance of emerging respiratory viruses is the rapid and early identification and placement of 57 
control measures [20].  Following the initial description of the disease [1], the ministry of health 58 
in the Kingdom of Saudi Arabia put in place a surveillance and screening program for admitted 59 
patients with respiratory illness [21].  Similarly, we adopted universal screening of admitted 60 
patients with community acquired pneumonia.  Here, we report the result of the surveillance 61 
activity in a general hospital in Saudi Arabia over a four year period.    62 
Materials and Methods: 63 
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The study was conducted at a 350-bed general hospital, which also accepts referred patients.  64 
The hospital provides medical care for about 160,000 individuals eligible for medical care.   The 65 
hospital has 5 intensive care units (cardiac, medical, surgical, pediatric, and neonatal) [22].  All 66 
admitted patients with community acquired pneumonia from 2012 to 2016 were tested for 67 
MERS-CoV.  The case definition of suspected MERS-CoV was an acute febrile respiratory 68 
illness (fever, cough, or dyspnea) with radiographic evidence of pneumonia [22].  We collected 69 
data for all suspected patients using a standard Microsoft Excel data collection sheet.  Both 70 
electronic and paper medical records were reviewed.  We recorded the age and the date of 71 
admission and the MERS-CoV and influenza results.  The study was approved by the Johns 72 
Hopkins Aramco Healthcare Institutional Review Board (IRB). 73 
MERS-CoV and Influenza Testing: 74 
Suspected patients had either Dacron-flocked nasopharyngeal swabs, or sputum testing for 75 
MERS-CoV.  The testing was done atthe Saudi Ministry of Health MERS-CoV laboratory and at 76 
the main hospital.  Clinical samples were screened with real-time reverse-transcriptase (RT)-77 
PCR as described previously [23].  The test amplified both the upstream E protein (upE gene) 78 
and ORF1a for MERS-CoV and if both assays were positive then the diagnosis of MERS-CoV 79 
was made, as described previously  [14].  The influenza test was carried out at the Johns Hopkins 80 
Aramco Healthcare Centre, Dhahran, using the Cepheid® Xpert Flu assay multiplex real-time 81 
PCR.  The tested influenza viruses were pandemic 2009 H1N1, Influenza A (other than H1N1), 82 
and Influenza B.  The test was systematically carried out starting April 2015.   83 
 84 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
 85 
 86 
Statistical Analysis: 87 
Statistical analysis was done using Excel and descriptive analyses were done for demographic, 88 
results of the tests and the monthly number of cases.  Minitab® (Minitab Inc. Version 17, 89 
PA16801, USA; 2017) was used to calculate the mean age (+ SD) of patients with influenza. 90 
Results: 91 
During the study period from 2013 to 2016, a total of 2657 patients were screened for MERS-92 
CoV and only 20 (0.74%) tested positive.  During the first two years (April 2013-March 2015), a 93 
total of 1013 patients were screened for MERS-CoV.  Only 1.8% of them were positive for 94 
MERS-CoV (Table 1) and unfortunately these were not systematically screened for influenza.  95 
There was an increased number of tests in November 2015-March 2016 (Figure 1). 96 
From April 2015 to December 2016, a total of 1644 patients were tested for both MERS-CoV 97 
and influenza.  None of the patients tested positive for MERS-CoV and 271 (16.4%) were 98 
positive for influenza.  The detected influenza viruses were Influenza A (107, 6.5%), pandemic 99 
2009 H1N1 (n= 120, 7.3%), and Influenza B (n=44, 2.7%) (Table 1 and figure 2).  It is 100 
interesting to note the pattern of the influenza in 2015 and 2016 (figure 3).  Pandemic H1N1 was 101 
the most common influenza in 2015 and influenza A other than H1N1 was more common in 102 
2016.  The 2015 influenza season peaked October to December and the 2016 season had a peak 103 
in August and then October to December (figure 3).  There was a significant difference in the 104 
mean age (+ SD; 95% CI) of patients with H1N1 and other influenza (Figure 4).  The mean age 105 
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(+ SD; 95% CI) was 45.09   (+24.32; 40.85, 49.33) for H1N1, 63.70   (+20.34; 59.21, 68.19) for 106 
influenza A, 55.11 (+25.27; 48.11, 62.12) for Influenza B, and 61.28 (+23.82; 60.03, 62.54) for 107 
influenza negative patients (P < 0.0001). 108 
Discussion: 109 
In this study, we presented the surveillance data on MERS-CoV over a four year period and the 110 
surveillance for influenza over a two year period.  MERS-CoV was only detected in 20 (0.75%) 111 
from a total of 2657 patients as detailed in previous publication [22,24].  The earliest 112 
surveillance study from Saudi Arabia was done from 1 October 2012 to 30 September 2013 and 113 
tested a total of 5065 samples [21].   In that study, the MERS positivity rate was 2% [21].  A 114 
second surveillance of MERS-CoV in Saudi Arabia was conducted from April 1, 2015 to 115 
February 1, 2016 and included a total of 57,363 suspected MERS cases [25].  The study showed 116 
only 384 (0.7%) MERS-CoV positive cases [25].  In a study in the United States, two (0.4%) 117 
imported cases were detected among 490 patients-under investigation in 2013-2014 [26].  In a 118 
surveillance study of 1586 unique persons from the United Arab Emirates between January 1, 119 
2013and April 17, 2014, 41 (3%) tested positive for MERS-CoV infection [27].  In the South 120 
Korea outbreak, 184 (1%) had MERS among 16752 suspected cases [28].  In a small study from 121 
Saudi Arabia, MERS-CoV was not detected in 182 cases tested November 2013 and January 122 
2014 (winter time) [29].  Thus, the overall positivity of MERS-CoV among a large cohort 123 
remains low.  There is a need for a better tool to identify patients with high probability of 124 
MERS-CoV.  However, a case control study and a large cohort study did not reveal significant 125 
predictor of MERS-CoV infection [22,30].  126 
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The monthly frequency of suspected MERS cases that were tested showed variation with an 127 
apparent increase in the tested number during November 2015-March 2016.  This apparent 128 
increase likely represented an increased activity of influenza during that time.  There was no 129 
relation to the Hajj season as it occurred during September 21-26, 2015 (Figure 1).  In addition at 130 
that time, there were no known outbreaks in the Kingdom of Saudi Arabia to account for such an 131 
increase in the testing.  The 2015 outbreaks occurred in Al-Hasa in May 2015 [31] and in Riyadh 132 
in August 2015 [7,32,33]. Previous studies had shown increased testing of patients for MERS-133 
CoV during outbreaks [4].  The In the current study, 2015 season was predominated by 2009 134 
pandemic H1N1 whereas influenza A was more common during 2016. Similarly, in the United 135 
States the 2014-2015 season was predominated by pandemic H1N1 and H3N2 was more 136 
common during the 2016-2017 season [34,35].We found that influenza rather than MERS-CoV 137 
was more common among the tested patients.  The findings are also consistent with other studies 138 
among travelers and pilgrims where influenza far exceeded MERS [36–40].  Similarly, in a small 139 
study in Saudi Arabia, influenza viruses were detected in 16% [29].  Similarly, among a small 140 
study of 52 suspected MERS cases in the United States of America, Influenza was the most 141 
commonly (35%)  identified respiratory agent [41] and another study found influenza A and B in 142 
11% of 296 investigated patients [26].  Thus, it is important to test for common respiratory 143 
pathogens such as influenza viruses and it should be noted that identification of a respiratory 144 
pathogen should not exclude MERS-CoV testing [42].  One report indicated co-infection with 145 
influenza and MERS in four patients [43]. However, epidemiologic differences between different 146 
countries should remain as an important predictor of the existence of MERS-CoV infection. 147 
The mean age of patients with H1N1 was younger than the other influenza patients of at least 10 148 
years (45.09 vs. 63.70 for influenza A, 55.11 for Influenza B, and 61.28 for influenza negative 149 
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patients (P < 0.0001).  The inital cases of pandemic 2009 H1N1 were also younger than the 150 
influenza negative patients [44].  In a small study of 196 patients, influenza B patients were 151 
younger than other influenza [45] and in another study the mean age was lower for patients with 152 
influenza B (16.4 yr) than (H1N1) pdm09 influenza infection.  However, these studies included 153 
children and thus are not compareable with the present study [46]. 154 
Similar results were obtained in travelers returning from the Middle East.  These studies showed 155 
the lack of MERS-CoV among travelers and that influenza was more common among French 156 
travelers [47,48],  Austrian returning pilgrims [40], British travelers [49], German travelers [50], 157 
and travelers to California, United States [41].  The presence of influenza infection among those 158 
travelrs stress the need for influenza vaccination in travelers, notably tfor those going for the Hajj 159 
and Umrah in Saudi Arabia.  160 
In conclusion, MERS-CoV was a rare cause of CAP and other viral causes including influenza 161 
are much more common.  The epidemiology of influenza mirrored the epidemiology of influenza 162 
worldwide.  The study highlights the importance of the surveillance system to elucidate the 163 
epidemiology of respiratory infections in order to formulate appropriate control measures.  Inter-164 
hospital and intra-hospital transmission of MERS-CoV infection is an important element of the 165 
transmission of this virus and it is imperative to continue to have early recognition of cases and 166 
constant application of infection control measures to abort the hospital transmissions of the virus 167 
[18,19]. 168 
 169 
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 362 
Table 1: Number of positive tests for influenza and MERS-CoV in relation to the study 363 
period 364 
Study Period MERS-
CoV 
Influenza A H1N1 Influenza B Grand Total 
4/2013-3/2015 20 (1.8) ND ND ND 1092 
4/2015-12/2016 0 (0) 107 (6.5) 120 (7.2) 44 (2.6) 1644 
Overall 20 (0.74)    2736 
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Figure 3: A Line graph showing the monthly number of isolated influenza by type  391 
 392 
 393 
 394 
 395 
 396 
 397 
 398 
 399 
 400 
 401 
0
5
10
15
20
25
30
35
Influenza A
H1N1
Influenza B
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
23 
 
Figure 4:  Interval Plot of Age and 95% Confidence Interval of Age among Influenza 402 
Patients 403 
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